Show simple item record

BASELINE CIRCULATING TUMOR CELL COUNTS SIGNIFICANTLY ENHANCE A PROGNOSTIC SCORE FOR PATIENTS PARTICIPATING IN PHASE I ONCOLOGY TRIALS

dc.contributor.authorBaird, RD
dc.contributor.authorSandhu, S
dc.contributor.authorYap, T
dc.contributor.authorMassard, C
dc.contributor.authorPapadatos-Pastos, D
dc.contributor.authorOlmos, D
dc.contributor.authorDukes, J
dc.contributor.authorGrainger, P
dc.contributor.authorPope, L
dc.contributor.authorDe Bono, J
dc.coverage.spatialBrussels, BELGIUM
dc.date.accessioned2018-06-26T10:50:22Z
dc.date.issued2011-05-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290610100066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9
dc.identifier.citationANNALS OF ONCOLOGY, 2011, 22 pp. 41 - 41 (1)
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1936
dc.format.extent41 - 41 (1)
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.titleBASELINE CIRCULATING TUMOR CELL COUNTS SIGNIFICANTLY ENHANCE A PROGNOSTIC SCORE FOR PATIENTS PARTICIPATING IN PHASE I ONCOLOGY TRIALS
dc.typeOther
rioxxterms.licenseref.startdate2011-05-01
rioxxterms.typeOther
dc.relation.isPartOfANNALS OF ONCOLOGY
pubs.finish-date2011-05-07
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.start-date2011-05-05
pubs.volume22
pubs.embargo.termsNot known
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorYap, Timothyen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record